accord
recent
unaid
estim
million
peopl
infect
human
immunodefici
viru
hiv
million
die
sinc
start
aid
epidem
end
million
peopl
live
hiv
global
million
new
hiv
infect
hiv
continu
spread
mainli
heterosexu
sex
although
aid
vaccin
research
made
great
progress
past
year
mani
neutral
antibodi
ctl
epitop
vaccin
vector
discov
fdaapprov
vaccin
avail
current
henc
altern
prevent
method
need
supplement
educ
behavioralmodif
program
infect
individu
worldwid
women
acquir
hiv
infect
sexual
contact
present
best
strategi
accomplish
block
hiv
mucos
transmiss
local
spread
femal
genit
tract
involv
design
implement
topic
microbicid
use
sex
interfer
viral
transmiss
microbicid
prevent
sexual
transmiss
either
destroy
microb
prevent
infect
target
cell
small
molecul
cellulos
acet
cap
bind
viral
glycoprotein
prevent
attach
receptor
small
molecul
bind
inhibit
associ
protect
nonhuman
primat
mani
natur
product
genistein
curcumin
also
found
inhibit
hiv
infect
algal
lectin
cyanovirinn
scytovirin
griffithsin
exhibit
high
antihiv
activ
cyanovirinn
extens
investig
microbicid
thu
far
howev
lack
solubl
bioavail
limit
clinic
applic
led
fail
clinic
trial
chitosan
natur
biocompat
cation
polysaccharid
deriv
crustacean
shell
use
dietari
supplement
weight
loss
also
shown
antimicrobi
properti
importantli
chitosan
also
shown
antihiv
properti
similar
action
microbicid
kill
inactiv
hiv
stop
viru
enter
human
cell
inhibit
hiv
replic
potenti
enhanc
bodi
normal
defens
mechan
hiv
thu
low
molecular
weight
sulphat
chitosan
shown
block
viral
entri
viruscel
fusion
probabl
via
disrupt
bind
cell
surfac
receptor
intravagin
mucoadhes
chitosan
microspher
tenofovir
disoproxil
fumar
tdf
also
shown
stabl
month
also
thiolat
chitosan
shown
enhanc
retain
topic
microbicid
longer
tenofovir
recent
chitosan
oligom
conjug
tripeptid
tryptophan
methionin
glutamin
shown
activ
inhibit
syncytia
format
upon
cocultur
hivinfect
uninfect
cell
investig
use
chitosan
tool
genesilenc
use
vectordriven
express
sirna
shown
promis
treat
viral
infect
advantag
vector
driven
sirna
includ
eas
construct
plasmid
vector
devoid
viral
gene
stabil
heat
resist
possibl
combin
sirna
viru
andor
host
gene
form
therapi
cocktail
eas
prepar
costeffect
plasmid
vector
use
replic
mammalian
host
integr
host
genom
yet
persist
host
cell
express
sirna
period
day
week
sever
report
indic
target
viral
protein
cellular
receptor
coreceptor
sirna
significantli
inhibit
replic
vitro
howev
use
sirna
approach
mucos
vagin
gene
transfer
form
microbicid
explor
major
challeng
earli
vagin
rectal
microbicid
caus
denud
mucos
epithelium
promot
hiv
also
potenti
viral
bacteri
infect
chitosan
antimicrobi
antihiv
activ
woundheal
properti
cytotox
activ
facilit
mucos
gene
deliveri
use
combin
chitosanbas
nanoparticl
sirna
prepar
potent
microbicid
present
studi
herein
report
novel
chitosanlipid
chlipid
nanoparticl
cn
deliv
plasmid
encod
sirna
protect
infect
vivo
base
success
use
chitosannanoparticl
deliv
sirna
mice
test
cocktail
antihiv
sirna
nanoparticl
prevent
transmiss
macaqu
model
pilot
studi
result
show
antihiv
sirna
microbicid
cocktail
select
deliv
cn
hivsuscept
cell
mucos
tissu
watersolubl
chitosan
mgml
mix
lipofectamin
invitrogen
ratio
chitosan
lipofectamin
total
volum
vortex
min
room
temperatur
later
chlipid
nanocomplex
mix
respect
dna
total
psirna
vitro
studi
mixtur
contain
cn
dna
psirna
vortex
min
room
temperatur
administr
six
differ
sirna
target
tat
rev
gag
ltr
rhesu
macaqu
design
clone
vector
ambion
accord
manufactur
specif
sirna
develop
base
recombin
simianhuman
immunodefici
viru
chimer
lentivirus
name
shiv
consist
backbon
hiv
type
envelop
env
regulatori
gene
hivspecif
sirna
clone
bamhi
hindiii
site
ambion
top
strand
bottom
strand
sirnaencod
dna
oligonucleotid
synthes
bamhi
site
includ
end
sirna
addit
random
nucleotid
flank
sequenc
hindiii
site
includ
end
sirna
nucleotid
flank
sequenc
sirna
contain
sirna
sens
element
ident
target
gene
sequenc
loop
region
follow
nt
antisens
element
doublet
overhang
sirna
target
sequenc
sens
element
posit
nt
ltr
nt
gag
nt
tat
nt
rev
genom
nt
rhesu
macaqu
nt
rhesu
macaqu
top
strand
bottom
strand
sirnaencod
oligonucleotid
anneal
digest
clone
primer
pair
respect
sirna
shown
tabl
cell
cotransfect
sirna
provir
dna
viral
supernat
collect
h
transfect
level
measur
elisa
kit
beckman
coulter
similarli
human
pbmc
cultur
grown
plate
cotransfect
electropor
vectordriven
sirna
plu
provir
dna
viral
supernat
collect
h
transfect
examin
level
elisa
cell
grown
plate
cotransfect
vectordriven
sirna
psiltr
psitat
psirev
psigag
vector
control
along
provir
dna
use
cn
viral
supernat
collect
h
transfect
level
measur
use
elisa
kit
beckman
coulter
normal
neg
control
threedimension
vagin
ectocerv
tissu
procur
mattek
corpor
tissu
maintain
per
manufactur
instruct
tissu
transfect
chitosan
lipofectamin
cn
combin
pegfp
h
posttransfect
tissu
fix
formalin
paraffinembed
immunostain
use
antigfp
antibodi
tag
alexa
fluor
invitrogen
nuclearstain
dapi
tissu
also
cotransfect
either
cocktail
plasmid
sirnascn
vector
controlcn
cn
alon
without
plasmid
along
provir
dna
h
wash
pb
fresh
medium
ad
elisa
perform
supernat
collect
day
titrat
concentr
pgml
safeti
system
administ
cn
evalu
femal
balbc
mice
jackson
laboratori
bar
harbor
n
maintain
pathogenfre
condit
univers
south
florida
colleg
medicin
vivarium
mice
given
intranas
lipofectamin
plasmid
dna
encod
enhanc
green
fluoresc
protein
egfp
mice
sacrif
day
lung
lavag
ml
pb
introduc
trachea
bal
fluid
centrifug
min
x
g
cell
rins
pb
resuspend
mice
given
pb
control
pool
cell
four
mice
also
quantifi
flow
cytometri
determin
egfp
transfect
level
bal
cell
mice
bal
fluid
analyz
content
use
elisa
r
system
minneapoli
mn
improv
rvi
model
use
evalu
microbicid
formul
effect
tissu
analys
histopatholog
cellular
infiltr
apoptosi
mucos
permeabl
cervicovagin
lavag
cvl
supernat
evalu
cytokin
leukocyt
marker
cell
pellet
use
quantit
phenotyp
measur
activ
statu
leukocyt
studi
chlipid
plasmid
sirna
cocktail
mix
antiinflammatori
cream
inc
tampa
fl
administ
intravagin
healthi
rabbit
increas
number
leukocyt
cvl
determin
termin
treatment
three
group
consist
two
femal
rabbit
maintain
environment
condit
dose
daili
either
mg
cream
alon
cream
plu
cn
mixtur
cream
plu
cn
contain
plasmid
sirna
cocktail
consist
sitat
sirev
ltr
sigag
per
plasmid
anim
day
serum
ml
cvl
fluid
ml
collect
rabbit
day
treatment
safeti
system
administ
cn
assess
nonhuman
primat
rhesu
monkey
via
ip
oral
rout
eight
femal
rhesu
monkey
kg
divid
two
group
blood
drawn
anim
day
baselin
valu
paramet
toxic
studi
anim
treatment
group
n
inject
ip
ml
mgml
chitosan
solut
fed
mg
chitosan
daili
week
control
group
n
anim
inject
ip
ml
pb
feed
chitosan
addit
blood
drawn
day
chitosan
feed
blood
chemistri
determin
individu
anim
assess
efficaci
plasmid
sirna
cocktail
consist
repres
sitat
sigag
ltr
sirev
per
plasmid
anim
evalu
efficaci
prevent
hiv
infect
rhesu
monkey
group
five
cycl
rhesu
monkey
weigh
kg
neg
type
retroviru
siv
simian
tlymphotrop
viru
stlv
select
vivo
experi
macaqu
use
pretreat
singl
intramuscular
dose
depoprovera
mganim
day
studi
group
five
macaqu
divid
control
treatment
monkey
mixtur
cream
mg
cn
contain
psirna
cocktail
appli
vagin
day
control
group
receiv
mixtur
cream
cn
day
anim
inocul
vagin
shiv
procur
nih
anim
bled
period
day
plasma
viral
load
measur
viral
rna
isol
plasma
collect
edtacontain
vial
accord
instruct
provid
manufactur
highpur
viral
rna
kit
roch
briefli
isol
rna
subject
revers
transcript
pcr
amplif
region
gag
later
amplifi
product
quantifi
antidig
enzymelink
immunosorb
assay
pcr
enzymelink
immunosorb
assay
dig
detect
roch
accord
manufactur
instruct
use
probe
nm
concentr
cat
ttg
gat
tag
cag
aaa
gcc
tgt
tgg
aga
aca
aag
aag
sampl
test
duplic
standard
use
cultur
supernat
contain
free
shiv
aliquot
dilut
plasma
sero
neg
macaqu
collect
edta
five
macaqu
control
treatment
anim
infect
shiv
titer
determin
rna
copiesml
post
infect
viral
titer
measur
absorb
read
nm
infect
viral
rna
copi
number
estim
base
standard
curv
chitosan
mgml
lipofectamin
invitrogen
mix
ratio
form
typic
cn
view
electron
microscop
suggest
cn
smaller
size
nm
compar
parent
chitosan
polym
nm
fig
cn
evalu
transfect
effici
vivo
use
mous
lung
lavag
assay
plasmid
encod
egfp
complex
chitosan
lipofectamin
cn
administ
intranas
h
later
bal
cell
collect
gfp
express
pool
lung
lavag
examin
flow
cytometri
cn
show
transfect
effici
oppos
classic
chitosan
lipofectamin
nake
dna
fig
moreov
littl
found
bal
cncomplex
pegfp
group
compar
chitosancomplex
group
fig
cell
grown
plate
cotransfect
vectordriven
sirna
psiltr
psitat
psirev
psigag
vector
control
along
provir
dna
use
lipofectamin
viral
supernat
collect
h
transfect
level
measur
elisa
normal
neg
control
screen
led
identif
sirna
plasmid
gave
least
threelog
decreas
hiv
titer
measur
result
show
signific
reduct
titer
individu
psirna
fig
use
independ
signific
decreas
viral
titer
data
shown
contrast
cell
studi
human
pbmc
cultur
grown
plate
incub
singl
dose
cell
psirna
cocktail
cn
psicocktail
vector
controlcn
cn
alon
without
plasmid
viru
infect
final
concentr
pgml
h
viru
remov
h
infect
centrifug
cell
wash
fresh
medium
ad
supernat
collect
day
level
determin
elisa
result
suggest
cocktail
psirna
decreas
hiv
titer
significantli
day
compar
panel
fig
vlcft
provid
ideal
surrog
model
test
cn
microbicid
target
safeti
efficaci
test
potenti
cn
deliv
pegfp
variou
cell
vlcft
model
establish
use
normal
human
ectocerv
cell
nhec
cultur
maintain
airliquid
interfac
tissu
consist
epitheli
cell
el
dc
fibroblast
lamina
propria
lp
cultur
vlcft
tissu
section
incub
three
differ
complex
chitosan
lipid
cn
complex
pegfp
h
later
tissu
fix
paraffinembed
immunostain
antigfp
antibodi
experi
show
cn
deliv
marker
plasmid
effici
compar
chitosan
lipid
complex
pegfp
fig
determin
whether
transfect
cn
cultur
alter
cell
prolifer
tissu
section
incub
chitosan
lipid
cn
h
later
tissu
fix
paraffin
embed
immunostain
antibodi
tag
alexa
fluor
result
show
use
cn
transfect
reagent
effect
cell
prolifer
shown
stain
compar
control
cell
treat
chitosan
lipid
fig
vec
tissu
incub
either
cocktail
plasmid
sirnascn
psi
cocktail
vector
controlcn
con
cn
alon
without
plasmid
viru
h
infect
final
concentr
pgml
h
wash
pb
fresh
medium
ad
viru
control
normal
tissu
control
supernat
collect
day
titrat
concentr
pgml
use
viru
titer
measur
supernat
collect
day
treatment
psicocktail
show
signific
reduct
viru
titer
compar
con
cn
alon
result
suggest
administr
cocktail
plasmid
sirna
complex
cn
significantli
reduc
viru
titer
measur
elsia
pgml
day
control
viru
titer
plateau
day
fig
three
group
consist
two
femal
rabbit
maintain
environment
condit
dose
daili
either
mg
cream
alon
cream
plu
cn
mixtur
cream
plu
chlipid
contain
plasmid
sirna
cocktail
consist
sitat
sirev
sigag
per
plasmid
anim
day
serum
ml
cvl
ml
fluid
collect
rabbit
day
treatment
none
cell
rabbit
lavag
treat
cream
alon
cream
plu
cn
mixtur
cream
plu
chlipid
contain
plasmid
sirna
cocktail
show
stain
indic
rabbit
inflamm
irrit
h
e
stain
cell
rabbit
cvl
day
treatment
cocktail
plasmid
sirna
complex
chlipid
formul
cream
show
neutrophil
infiltr
fig
evalu
effect
plasmid
sirna
cocktail
evalu
system
safeti
chitosan
nanoparticl
nonhuman
primat
administ
chitosan
rhesu
monkey
via
ip
oral
rout
tabl
summar
blood
chemistri
data
averag
group
result
suggest
treatment
chitosan
nanoparticl
caus
toxic
rhesu
monkey
respect
protein
total
protein
albumin
bilirubin
alkalin
phosphatas
aspart
aminotransferas
amylas
gammaglutamyl
transpeptidas
glucos
creatinin
lipid
triglycerid
cholesterol
inorgan
element
urea
nitrogen
calcium
phosphor
sodium
chlorid
magnesium
efficaci
cn
complex
plasmid
sirna
cocktail
consist
repres
sitat
sigag
ltr
sirev
per
plasmid
anim
prevent
shiv
infect
examin
pilot
studi
use
rhesu
monkey
fig
cream
formul
cn
contain
psirna
cocktail
appli
vagin
day
day
anim
inocul
intravagin
shiv
viral
stock
anim
bled
period
day
post
viru
challeng
plasma
viral
load
measur
pcr
enzymelink
immunosorb
assay
result
suggest
administr
cocktail
plasmid
sirna
complex
cn
prior
infect
significantli
reduc
viral
load
treat
monkey
day
infect
control
monkey
viral
load
plateau
follow
day
fig
review
preclin
clinic
research
develop
microbicid
formul
prevent
vagin
hiv
transmiss
yield
studi
preclin
clinic
current
microbicid
develop
effort
focus
compound
highli
potent
hivspecif
mechan
action
combin
product
novel
formul
care
design
pharmacokinet
pharmacodynam
evalu
product
phase
iii
nonspecif
microbicid
shown
moder
effect
preliminari
report
studi
latest
phase
iii
studi
pro
women
show
pro
offer
protect
hiv
howev
studi
enrol
women
south
africa
suggest
vagin
microbicid
contain
tenofovir
may
effect
sampl
size
rel
small
restrict
find
tenofovir
reduc
risk
hiv
transmiss
heterosexu
women
moreov
microbicid
base
neutral
antibodi
combin
four
firstgener
broad
neutral
antibodi
bnab
show
protect
challeng
human
blt
mous
model
studi
suggest
continu
investig
focus
earli
gener
novel
nonspecif
microbicid
result
also
rais
littl
doubt
junctur
agent
specif
action
hiv
antiretrovir
drug
target
sirna
offer
hope
rnai
wellcharacter
phenomenon
proven
effect
silenc
number
gene
differ
virus
sirna
introduc
cell
synthet
doubledstrand
oligonucleotid
previous
other
develop
dna
vectorbas
approach
introduc
sirna
tissu
cultur
system
vivo
hiv
hcv
rsv
sar
dengu
viru
well
virus
sirna
use
inhibit
target
variou
viral
protein
cellular
cofactor
import
hiv
replic
cellular
receptor
coreceptor
viral
tat
rev
gag
protein
among
success
target
first
report
sirna
target
dcsign
human
transcript
elong
factor
ptefb
cyclophilin
also
shown
effect
inhibit
replic
vitro
sirna
introduc
cell
synthet
doubledstrand
rna
effect
express
plasmid
control
rna
polymeras
iii
promot
silenc
reduc
express
cell
reduc
replic
fourfold
compar
control
degre
inhibit
similar
sirnatarget
test
pbl
differ
donor
fold
inhibit
synthet
sirna
effect
replic
pbmc
although
protect
transient
howev
sirna
target
tat
express
lentivir
vector
primari
macrophag
could
protect
infect
cultur
longer
period
sirna
target
viral
protein
especi
regulatori
protein
tat
rev
would
good
candid
gene
silenc
vivo
except
frequent
mutat
genom
could
abolish
effect
thu
cocktail
sirna
target
differ
gene
sequenc
would
like
avoid
mutant
escap
includ
sirna
target
coreceptor
addit
advantag
achiev
prevent
transmiss
sirna
target
coreceptor
affect
mutat
viral
genom
silenc
dcsign
sirna
also
significantli
inhibit
replic
presum
prevent
transfer
viru
dc
cell
dcsign
addit
target
control
futur
optim
psirna
cocktail
although
viral
titer
significantli
lower
group
treat
sirnabas
microbicid
around
day
complet
block
shiv
infect
obtain
studi
efficaci
nanomicrobicid
may
restrict
shivmacaqu
model
sigag
siltr
target
hiv
sequenc
instead
siv
sequenc
altern
option
test
efficaci
nanomicrobicid
human
blt
mice
challeng
human
mous
model
recogn
easi
approach
much
potenti
vaccin
studi
preclin
safeti
efficaci
test
microbicid
candid
involv
larg
number
vitro
ex
vivo
vivo
assay
model
demonstr
chitosanbas
nanoparticl
show
signific
toxic
rhesu
monkey
consist
modifi
chitosan
nanoparticl
sirna
deliveri
thu
sirnabas
chlipid
microbicid
describ
studi
subject
cautiou
rigor
preclin
evalu
assess
efficaci
model
use
microbicid
develop
